{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:23:35Z","timestamp":1794327815922,"version":"4.9.0"},"reference-count":39,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Checkpoint Therapeutics","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,9,15]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience inadequate responses or severe immune-related adverse events (AEs), indicating the need for improved therapies. Cosibelimab is a high-affinity programmed cell death-ligand 1 (PD-L1)-blocking antibody that activates innate and adaptive immunity by blocking PD-L1 interaction with PD-1 and B7-1 receptors. It is an unmodified immunoglobulin G1 subtype with a functional Fc domain capable of inducing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Here, we present results of the pivotal study of patients with metastatic CSCC from an open-label, multicenter, multiregional, multicohort, phase 1 trial of cosibelimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this trial, participants with metastatic CSCC received cosibelimab 800\u2009mg intravenously every 2 weeks. Primary endpoint was objective response rate (ORR) by independent central review using Response Evaluation Criteria in Solid Tumors, V.1.1. Secondary endpoints included duration of response (DOR) and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Objective response was observed in 37 of 78 participants (47.4% (95% CI: 36.0% to 59.1%)), with median follow-up of 15.4 months (range: 0.4 to 40.5) as of data cut-off. Median DOR was not reached (range: 1.4+ to 34.1+ months), with response ongoing in 73.0% of participants. Common treatment-emergent AEs (\u226515%) were fatigue (26.9%), rash (16.7%), and anemia (15.4%). Eighteen participants (23.1%) experienced immune-related AEs (grade 3: n=2 (2.6%); no grade 4\/5). No treatment-related deaths were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cosibelimab demonstrated clinically meaningful ORR and DOR and was associated with a manageable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03212404\">NCT03212404<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2023-007637","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T19:35:20Z","timestamp":1697571320000},"page":"e007637","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":56,"title":["Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03212404","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Philip","family":"Clingan","sequence":"first","affiliation":[{"name":"Southern Medical Day Care Centre, Wollongong, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Ladwa","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brungs","sequence":"additional","affiliation":[{"name":"Southern Medical Day Care Centre, Wollongong, New South Wales, Australia"},{"name":"Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean Laurence","family":"Harris","sequence":"additional","affiliation":[{"name":"Christchurch Hospital, Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"McGrath","sequence":"additional","affiliation":[{"name":"Medical Oncology, Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Arnold","sequence":"additional","affiliation":[{"name":"Exellentis Clinical Trial Consultants, George, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jermaine","family":"Coward","sequence":"additional","affiliation":[{"name":"ICON Cancer Centre, South Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Fourie","sequence":"additional","affiliation":[{"name":"Wilgers Oncology Centre, Pretoria, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Kurochkin","sequence":"additional","affiliation":[{"name":"Municipal Nonprofit Enterprise of Sumy Regional Council Sumy Regional Clinical Oncology Dispensary, Sumy, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R","family":"Malan","sequence":"additional","affiliation":[{"name":"Phoenix Pharma, Port Elizabeth, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mant","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Eastern Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Sharma","sequence":"additional","affiliation":[{"name":"Wits Clinical Research Chris Hani Baragwanath Clinical Trial Site, Johannesburg, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shue","sequence":"additional","affiliation":[{"name":"Sunshine Coast Haematology and Oncology Clinic, Buderim, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tazbirkova","sequence":"additional","affiliation":[{"name":"Medical Oncology, Pindara Private Hospital, Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5437-5196","authenticated-orcid":false,"given":"Miguel-Angel","family":"Berciano-Guerrero","sequence":"additional","affiliation":[{"name":"Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaiyut","family":"Charoentum","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon - Hopital Lyon Sud, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunee","family":"Dechaphunkul","sequence":"additional","affiliation":[{"name":"Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandr","family":"Dudnichenko","sequence":"additional","affiliation":[{"name":"Kharkiv Medical Academy of Postgraduate Education, Chair of Oncology and Children\u2019s Oncology, Clinical base State institution \u201cVT Zaycev Institute of General and Urgent Surgery of National Academy Medical Sciences of Ukraine\", Kharkiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Koralewski","sequence":"additional","affiliation":[{"name":"Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie Sp. z o.o., Oddzia\u0142 Onkologii Klinicznej z Pododdzia\u0142em Dziennym, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Lugowska","sequence":"additional","affiliation":[{"name":"Narodowy Instytut Onkologii im. Marii Sk\u0142odowskiej-Curie Pa\u0144stwowy Instytut Badawczy, Oddzia\u0142 Bada\u0144 Wczesnych Faz, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Montaudi\u00e9","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Nice - H\u00f4pital l'Archet, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[{"name":"Hospital Universitario Vall d'Hebron, Passeig de la Vall d'Hebron, Vall d\u2019Hebron Institute of Oncology (VHIO), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virote","family":"Sriuranpong","sequence":"additional","affiliation":[{"name":"King Chulalongkorn Memorial Hospital, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9857-1189","authenticated-orcid":false,"given":"James","family":"Oliviero","sequence":"additional","affiliation":[{"name":"Checkpoint Therapeutics Inc, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"2025100306031118000_11.10.e007637.1","doi-asserted-by":"crossref","unstructured":"Palyca P , Koshenkov VP , Mehnert JM . Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need. Am Soc Clin Oncol Educ Book 2014:e397\u2013404. doi:10.14694\/EdBook_AM.2014.34.e397","DOI":"10.14694\/EdBook_AM.2014.34.e397"},{"issue":"suppl 8","key":"2025100306031118000_11.10.e007637.2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/jdv.15845","article-title":"Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns","volume":"33 Suppl 8","author":"Amaral","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025100306031118000_11.10.e007637.3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020377","article-title":"The Multidisciplinary management of cutaneous squamous cell carcinoma: a comprehensive review and clinical recommendations by a panel of experts","volume":"14","author":"Stanganelli","year":"2022","journal-title":"Cancers"},{"key":"2025100306031118000_11.10.e007637.4","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1001\/jamadermatol.2020.3677","article-title":"Incidence of multiple vs first cutaneous squamous cell carcinoma on a nationwide scale and estimation of future incidences of cutaneous squamous cell carcinoma","volume":"156","author":"Tokez","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025100306031118000_11.10.e007637.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10830.x"},{"key":"2025100306031118000_11.10.e007637.6","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamadermatol.2020.3678","article-title":"Underestimation of cutaneous squamous cell carcinoma incidence, even in cancer registries","volume":"156","author":"Wehner","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025100306031118000_11.10.e007637.7","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12282"},{"key":"2025100306031118000_11.10.e007637.8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s12325-019-01130-1","article-title":"Recognising skin cancer in primary care","volume":"37","author":"Jones","year":"2020","journal-title":"Adv Ther"},{"key":"2025100306031118000_11.10.e007637.9","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40257-019-00426-w","article-title":"Immune checkpoint inhibitors for treating advanced cutaneous squamous cell carcinoma","volume":"20","author":"Patel","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2025100306031118000_11.10.e007637.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0941"},{"key":"2025100306031118000_11.10.e007637.11","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.31346","article-title":"Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"124","author":"Gold","year":"2018","journal-title":"Cancer"},{"key":"2025100306031118000_11.10.e007637.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1735"},{"key":"2025100306031118000_11.10.e007637.13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18632\/oncotarget.27434","article-title":"Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study","volume":"11","author":"Montaudi\u00e9","year":"2020","journal-title":"Oncotarget"},{"key":"2025100306031118000_11.10.e007637.14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.733917","article-title":"Immunotherapy for the treatment of cutaneous squamous cell carcinoma","volume":"11","author":"Boutros","year":"2021","journal-title":"Front Oncol"},{"key":"2025100306031118000_11.10.e007637.15","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"2025100306031118000_11.10.e007637.16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/17512433.2019.1665026","article-title":"Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma","volume":"12","author":"Ahmed","year":"2019","journal-title":"Expert Review of Clinical Pharmacology"},{"key":"2025100306031118000_11.10.e007637.17","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3498","article-title":"Update of the management of cutaneous squamous-cell carcinoma","volume":"100","author":"Maubec","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2025100306031118000_11.10.e007637.18","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13102"},{"key":"2025100306031118000_11.10.e007637.19","unstructured":"LIBTAYO\u00ae . Regeneron Pharmaceuticals, Inc; 2021."},{"key":"2025100306031118000_11.10.e007637.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int"},{"key":"2025100306031118000_11.10.e007637.21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2020.01.008","article-title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2. Treatment","volume":"128","author":"Stratigos","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025100306031118000_11.10.e007637.22","unstructured":"LIBTAYO\u00ae (cemiplimab) . Australian product information. Sanofi-Aventis Australia Pty Ltd; 2020."},{"key":"2025100306031118000_11.10.e007637.23","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100306031118000_11.10.e007637.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k793","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"key":"2025100306031118000_11.10.e007637.25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"key":"2025100306031118000_11.10.e007637.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.04.177"},{"issue":"Suppl 33","key":"2025100306031118000_11.10.e007637.27","doi-asserted-by":"crossref","first-page":"S4065","DOI":"10.21037\/jtd.2018.09.83","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer\": is there a substantial difference or not?","volume":"10","author":"Spagnuolo","year":"2018","journal-title":"J Thorac Dis"},{"issue":"13_Supplement","key":"2025100306031118000_11.10.e007637.28","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1158\/1538-7445.AM2017-4606","article-title":"Abstract 4606: Preclinical characterization of a novel fully human IgG1 anti-PD-L1 mAb CK-301","volume":"77","author":"Gorelik","year":"2017","journal-title":"Cancer Res"},{"key":"2025100306031118000_11.10.e007637.29","unstructured":"Lin L , Hilbert J , Gorelik L , et al . Semi-mechanistic PK and target-occupancy modeling to support dose justification for anti-PD-L1 clinical candidate CK-301 (cosibelimab) in oncology patients. Poster presented at: Society for Immunotherapy of Cancer 34th Annual Meeting; National Harbor, MD, 2019."},{"key":"2025100306031118000_11.10.e007637.30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"2025100306031118000_11.10.e007637.31","unstructured":"Lin L , Hillbert J , Gorelik L , et al . Semi-mechanistic PK and target-occupancy modeling to support dose justification for anti-PD-L1 clinical candidate CK-301 (TG-1501) in oncology patients [abstract P431]. Abstract presented at: Society for Immunotherapy of Cancer 34th Annual Meeting; National Harbor, MD, 2019."},{"key":"2025100306031118000_11.10.e007637.32","first-page":"69e","article-title":"Treatment of locally advanced and metastatic cutaneous squamous cell carcinoma","volume":"112","author":"Greco","year":"2021","journal-title":"Recenti Prog Med"},{"key":"2025100306031118000_11.10.e007637.33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100306031118000_11.10.e007637.34","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.6004\/jnccn.2021.0059","article-title":"NCCN guidelines\u00ae insights: squamous cell skin cancer, version 1.2022","volume":"19","author":"Schmults","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2025100306031118000_11.10.e007637.35","unstructured":"Cancer Council . UV index, Available: https:\/\/www.cancer.org.au\/cancer-information\/causes-and-prevention\/sun-safety\/uv-index [Accessed 24 May 2023]."},{"key":"2025100306031118000_11.10.e007637.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"2025100306031118000_11.10.e007637.37","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100306031118000_11.10.e007637.38","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.19.03357","article-title":"Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas","volume":"38","author":"Maubec","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100306031118000_11.10.e007637.39","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:03:29Z","timestamp":1759496609000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,17]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/jitc-2023-007637"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007637","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}